Trial Profile
A Phase 2b Study of Immune Checkpoint Inhibition With or Without Dorgenmeltucel-L (HyperAcute Melanoma) Immunotherapy for Stage IV Melanoma Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Dorgenmeltucel-L (Primary) ; Ipilimumab; Nivolumab; Pembrolizumab
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lumos Pharma; NewLink Genetics Corporation
- 27 Mar 2023 Status changed from active, no longer recruiting to discontinued.
- 29 Oct 2015 Treatment arms changed from 2 to 6 as reported by ClinicalTrial.gov record.
- 28 Oct 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Dec 2016 as reported by ClinicalTrial.gov record.